Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Amneal Pharmaceuticals, Inc.

NASDAQ: AMRX · Life Sciences · 3 alerts · CIK 1723128

Share price
$21.23Close, Nov 16
Market cap
$7.4B
Shares outstanding
348.41MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Amneal Pharmaceuticals, Inc. filings on SEC EDGAR ↗

4:22 PM ET 10-Q
Financial Results

Amneal Pharmaceuticals Q3 2026 Results: Net Loss of $21.7M

Amneal Pharmaceuticals reported net revenue of $862.7 million for the third quarter of 2026, an increase from $784.5 million in the prior year period. Despite higher operating income, the company recorded a net loss attributable to Class A common stockholders of $21.7 million for the quarter, primarily due to accretion of redeemable non-controlling interests and acquisition-related costs.

Key figure
Net loss $21.7M
8:08 AM ET 8-K
Financial Results

Amneal Pharmaceuticals Financial Results

Amneal Pharmaceuticals reported Q3 2026 net revenue of $863 million, a 10% increase year-over-year, driven by strong growth in biosimilars and specialty products. Despite the revenue growth, the company posted a GAAP net loss of $22 million due to acquisition and integration costs related to Kashiv. Consequently, Amneal raised its full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted EPS.

Term
Q3 2026

“Amneal delivered another quarter of strong, broad-based performance, enabling us to increase our 2026 guidance once more. As we prepare to enter 2027, our financial performance is accelerating driven by a number of key catalysts and new launches, including Women’s Health patches, biosimilars, injectables such as lanreotide, CREXONT®, and BREKIYA® autoinjector.”

Chirag and Chintu Patel, Co-Founders and Co-Chief Executive Officers
4:06 PM ET 8-K/A
M&A Deal

Amneal Pharmaceuticals M&A Deal with Kashiv BioSciences, LLC

Amneal Pharmaceuticals filed an amendment to its previous 8-K to provide required historical financial statements and pro forma financial information following its completed acquisition of Kashiv BioSciences, LLC. The acquisition was originally completed on August 10, 2026, pursuant to a Membership Interest Purchase Agreement dated April 21, 2026.

Counterparty
Kashiv BioSciences, LLC

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.